

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07K 15/06, A61K 35/16, 39/40 A61K 39/085, 39/395, 49/00 C12Q 1/00, G01N 33/536</p>	<p>A1</p>	<p>(11) International Publication Number: WO 93/17044 (43) International Publication Date: 2 September 1993 (02.09.93)</p>
<p>(21) International Application Number: PCT/US92/09830 (22) International Filing Date: 9 November 1992 (09.11.92) (30) Priority data: 804,317 25 February 1992 (25.02.92) US (71)(72) Applicant and Inventor: FISCHER, Gerald, W. [US/ US]; 6417 Lybrook Drive, Bethesda, MD 20817 (US). (74) Agent: BELLAMY, Werten, F., W.; Intellectual Property Law Division, Office of The Judge Advocate General, DA, 901 N. Stuart Street, Suite 400, Arlington, VA 22203-1837 (US).</p>		<p>(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, Euro- pean patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: DIRECTED HUMAN IMMUNE GLOBULIN FOR THE PREVENTION AND TREATMENT OF STAPHYLO- COCCAL INFECTIONS</p> <p>(57) Abstract</p> <p>This invention is directed to a Directed Human Immunoglobulin and compositions thereof for preventing or treating sta- phylococcal infections such as <i>S. epidermidis</i>.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

-1-

1 DIRECTED HUMAN IMMUNE GLOBULIN FOR THE PREVENTION
2 AND TREATMENT OF STAPHYLOCOCCAL INFECTIONS

3 I. GOVERNMENT INTEREST

4 The invention described herein may be manufactured, licensed
5 and used by or for governmental purposes without the payment of any royalties
6 to us thereon.

7 II. FIELD OF THE INVENTION

8 This invention relates to Directed Human Immune Globulin for
9 the prevention and treatment of staphylococcal infections.

10 III. BACKGROUND OF THE INVENTION

11 Over the last two decades, staphylococci have become important
12 causes of infection in hospitalized patients. Because of their high prevalence
13 on the skin, staphylococci are ideally situated to cause serious infections in
14 debilitated or immunosuppressed patients. The staphylococcal species most
15 frequently pathogenic in humans are Staphylococcus aureus (SA) and
16 Staphylococcus epidermidis (SE). Both groups have developed resistance to
17 multiple antibiotics making antimicrobial therapy difficult. In recent years SE
18 has become a major cause of nosocomial infection in patients whose treatments
19 include the placement of foreign materials such as cerebrospinal fluid shunts,

-2-

1 vascular catheters or joint prostheses. SE is a common cause of post operative
2 wound infections peritonitis in patients with continuous ambulatory peritoneal
3 dialysis. Patients with impaired immunity (malignancy, bone marrow
4 transplant) or those receiving parenteral nutrition through central venous
5 catheter are also at high risk for developing SE sepsis (Patrick, J. Pediatr.,
6 1990).

7 SE has emerged as a common cause of neonatal nosocomial
8 sepsis in premature infants. As shown by Fleer and colleagues, (Pediatr Infect
9 Dis, 1983) SE infections frequently occur in immature babies that have
10 received parenteral nutrition. Premature babies have impaired immunity with
11 deficiencies in antibodies, complement and neutrophil function. Lipid infusion
12 is now a standard ingredient of parenteral nutrition therapy in many nurseries
13 and may further impair immunity to bacterial infection as disclosed by Fischer
14 and colleagues (Lancet, 1980; 2:819-20). Recent studies have associated
15 coagulase negative staphylococcal bacteria in neonates with lipid emulsion
16 infusion (Freeman and colleagues, N. Engl. J. Med, 1990). Further studies by
17 Fleer and colleagues (J Inf Dis, 1985) showed that neonates had low levels of
18 opsonic antibody to SE despite the fact that the sera had clearly detectable
19 levels of IgG antibodies to SE peptidoglycan (opsonic antibodies for
20 staphylococcus have been considered to be directed to the peptidoglycan
21 antigens). While these studies suggested that neonatal susceptibility to SE
22 might be related to impaired opsonic activity, it is not clear if antibodies

-3-

1 directed against SE are opsonic or would be capable of providing protection
2 when given passively to neonates. Further, it is unknown whether the
3 presence of intralipid, which further impairs phagocytosis and killing of
4 bacteria by phagocytes, would inhibit the activity of antibody.

5 The opsonic activity of pooled human immunoglobulin for SE
6 was studied by Clark and colleagues (J Med Microbiol, 1986), and showed that
7 complement and IgG were both critical for efficient opsonization of SE. They
8 noted, however, that in some studies complement was not required and that
9 contrary to the report of Fleer (1985), absorption of serum with peptidoglycan
10 may remove the opsonic activity for SE. Further studies by Clark and Easmon
11 (1986) showed that several lots of standard intravenous immune globulin
12 (IVIG) had variable opsonic activity for SE. One third of the IVIG lots had
13 poor opsonization with complement and only 2 of 14 were opsonic without
14 complement. Despite the fact that the IVIG lots are made from large plasma
15 donor pools good opsonic antibody to SE was not uniformly present. Their
16 studies focused on potential use of immunoglobulin to boost peritoneal defenses
17 in patients receiving continuous ambulatory peritoneal dialysis and did not
18 examine whether IVIG could be utilized for the prevention or treatment of
19 bacterial sepsis, or the use of antibody to prevent or treat sepsis and lethal
20 infection in immature or immunosuppressed patients and Specifically, no in
21 vivo studies were done to test antibody to prevent or treat

-4-

1 SE. There is no evidence therefore that the antibody would provide beneficial
2 therapy in a setting of immaturity or impaired immunity.

3 The opsonic assays, that are currently used are slow and
4 cumbersome for screening blood, plasma or immune globulin for antibodies to
5 SE. It would be important to have a rapid antigen binding assay to screen for
6 SE antibody, if that assay further correlated with opsonic activity in vitro and
7 protection in vivo.

8 In order to determine if IgG is capable of enhancing protection
9 against SE, a suitable animal model that is comparable to patients with SE
10 infections is required. This is critical since neonates have low levels of
11 complement and impaired neutrophil and macrophage function. While opsonic
12 activity of immune globulin may be adequate under optimal conditions in vitro,
13 protection may not occur in patients with immature or impaired immune
14 systems. As has been demonstrated by Clark and colleagues (J Clin Pathol,
15 1986), most IVIG preparations were not opsonic when complement was
16 removed. However, since SE has low virulence, suitable animal models of SE
17 sepsis have not been available.

18 Yoshida and colleagues, (J Microbiol, 1976) reported on a
19 virulent strain of SE that infected mature mice with 90 - 100% of mice dying
20 within 24 - 48 hours. This model is very different from that seen in patients
21 and may represent an unusual type of SE infection. When they analyzed 80
22 fresh isolates of SE from humans, they were not able to kill mice. Non-human

-5-

1 antibody to a new SE surface polysaccharide protected the mice from the
2 virulent SE strain. A later report by Yoshida and colleagues (J Med
3 Microbiol, 1977) confirmed their previous observations. Passive prophylaxis
4 with immunization induced non-human antibody showed that the IgG fraction
5 did not protect while the IgM fraction did provide protection. Thus
6 demonstrating in this model that IgG antibody was not protective. As noted
7 previously herein neonates had good levels of IgG to SE, but had low levels of
8 opsonic antibody (Fleer and colleagues, J. Infect. Dis, 1985), consistent with
9 the findings in this study and showing that the role of IgG in protection against
10 SE is unclear. In 1987 the report by Ichiman and colleagues (J Appl Bacteriol,
11 1987) extended their animal studies to include analysis of protective antibodies
12 in human serum against their selected virulent strains of SE. Protective
13 antibody was found in the IgA, IgM and IgG immunoglobulin fractions. These
14 studies are in conflict with their previous data showing that IgG was not
15 protective and fails to establish a definitive role for any of the immunoglobulin
16 classes (IgG, IgM or IgA).

17 In the animal model described by Yoshida, Ichiman and
18 colleagues mature, non-immunosuppressed mice were used and death was
19 considered to be related to toxins not sepsis (Yoshida and colleagues, J.
20 Microbiol, 1976). Most clinical isolates did not cause lethal infections in their
21 model. Since quantitative blood cultures were not done, it is not known
22 whether antibody would prevent or treat SE sepsis in immature

-6-

1 immunosuppressed patients or specifically in the presence of intralipid.

2 Antibody provides protection in humans against certain

3 encapsulated bacteria such as Hemophilus influenzae and Streptococcus

4 pneumoniae. Individuals such as young infants who are deficient in antibody

5 are susceptible to infections with these bacteria and bacteremia and sepsis are

6 common. When antibody to these bacteria is present it provides protection by

7 promoting clearance of the bacteria from the blood. Immunoglobulin with

8 antibody to H. influenzae and S. pneumoniae protects infants from sepsis with

9 these bacteria. The article by Espersen and colleagues, (Arch Intern Med,

10 1987) discloses the use of an antigen binding RIA assay to analyze IgG

11 antibody to SE in patients with uncomplicated bacteremia and those with

12 bacteremia and endocarditis. This assay used an ultrasonic extract of SE to

13 identify SE specific IgG (the surface antigen in this study differs from the

14 antigen used by Yoshida and colleagues which was obtained by a different

15 method; gentle sonic oscillation). None of the patients with uncomplicated

16 bacteremia had IgG antibodies to SE. These data would suggest that IgG is

17 unnecessary for effective eradication of SE from the blood. In addition, 89%

18 of bacteremic patients with endocarditis developed high levels of IgG to SE.

19 In these patients, IgG was not protective since high levels of IgG antibody

20 (which may have developed late) were associated with serious bacteremia and

21 endocarditis. Based on these studies the protective role of IgG in SE sepsis

22 and indocarditis is not established, especially in the presence of immaturity,

-7-

1 debilitation, intralipid infusion, or immunosuppression. In addition, the
2 extensive review of Patrick et al. (J. Pediat., 1990) does not include
3 immunoglobulin as a potential prophylactic or therapeutic agent for SE
4 infections.

5 It has been recognized by the medical community that SE is an
6 important pathogen in certain high risk individuals, such as patients with
7 foreign body implants, premature neonates and immunosuppressed patients.
8 Accordingly there is a need for a human immune globulin that would prevent
9 or treat SE infections such as, sepsis or endocarditis and promote clearance of
10 SE from the blood of such high risk people.

11 IV. SUMMARY OF THE INVENTION

12 It is therefore an object of the present invention to provide a
13 novel Directed Human Immune Globulin for preventing or treating
14 staphylococcal infections. We have found that it is useful to screen serum
15 (plasma) or pooled immunoglobulin for specific antibody to S. epidermidis to
16 produce Directed Human Immune Globulin to this pathogen. This Directed
17 Human Immune Globulin is different from standard human immune globulin
18 preparations in that it has high levels of human anti-staphylococcal antibodies
19 that react with surface antigens of S. epidermidis and enhance phagocytosis
20 and killing of S. epidermidis in vitro, (opsonophagocytic bactericidal activity
21 greater than 80%). In addition, Directed Human Immune Globulin for S.

-8-

1 epidermidis enhances immunity in vivo and prevents lethal infection as well as
2 enhancing clearance of S. epidermidis from the blood in conditions of
3 immaturity and impaired immunity. This is surprising since
4 immunosuppression or immaturity would be expected to render the antibody
5 ineffective by impairing the ability of phagocytic cells to engulf and kill the S.
6 epidermidis.

7 It is also another advantageous object of the present invention
8 that while standard immunoglobulin pools or normal donors do not have
9 reliable levels of opsonic antibody for S. epidermidis, Directed Human
10 Immune Globulin when given intravenously immediately provides specific
11 antibodies to promote phagocytosis and killing of S. epidermidis by
12 phagocytes. A further advantages of the present invention is that by providing
13 opsonic antibody to immature or immunosuppressed patients infected with SE,
14 antibiotic therapy may be enhanced by improved S. epidermidis clearance from
15 the blood or site of infection. Another advantage is that since Directed Human
16 Immune Globulin given intravenously or intramuscularly can raise the level of
17 antibodies in the blood of patients, Directed Human Immune Globulin could
18 prevent S. epidermidis from causing bacteremia and local infections.

19 The method of producing the Directed Human Immune Globulin
20 for S. epidermidis involves:

21 a) screening plasma (pools of immunoglobulin or plasma;
22 immunoglobulin or immunoglobulin preparations) for antibodies to S.

-9-

1 epidermidis using an in vitro antigen-binding assay: (ELISA), followed by
2 confirmation of functional activity using an in vitro opsonophagocytic
3 bactericidal assay (bactericidal activity greater than 80%).

4 b) Protective efficacy can be documented in vivo by
5 analyzing protective activity of the Directed Human Immune Globulin using a
6 suckling rat model of neonatal S. epidermidis sepsis (mortality and bacterial
7 clearance). We believe that this is the first in vivo model to test antibody
8 effectiveness in the presence of immaturity and/or intralipid induced immune
9 suppression.

10 These methods could be repeated using other staphylococci such as SA
11 instead of SE to produce Directed Human Immune Globulin for S. aureus.

12 This novel Directed Human Immune Globulin for SE could be used to
13 prevent lethal SE infections in high risk patients such as neonates and adults in
14 intensive care units or patients with in-dwelling foreign bodies such as venous
15 and arterial catheters or ventricular shunts. Directed Human Immune Globulin
16 could also be used in addition to antibiotics as adjunctive therapy to enhance
17 bacterial clearance in patients treated for SE infections.

18 Other objects, features and advantages of the present invention will
19 become apparent from the following detailed description. It should be
20 understood, however, that the detailed description and specific examples, while
21 indicating preferred embodiments of the invention, are given by way of
22 illustration only, since various changes and modifications within the spirit and

-10-

1 scope of the invention will become apparent to those skilled in the art from
2 this detailed description.

3 The terms Standard Human Immunoglobulin and Directed
4 Human Immune Globulin for S. epidermidis as used in this application are
5 defined as follows: Standard Human Immunoglobulin - immune human
6 globulin that was prepared by pooling immunoglobulin from many donors,
7 without selecting donors or screening the immunoglobulin to ensure antibody
8 activity for S. Epidermidis.

9 Directed Human Immune Globulin for S. epidermidis - Immune
10 globulin prepared by screening for antibody to S. epidermidis (Bactericidal
11 Activity > 80%), thereby providing a human immune globulin with protective
12 levels of antibody to S. epidermidis and suitable for preventing or treating S.
13 epidermidis infections. Bactericidal Activity-The percentage of bacteria killed
14 with the addition of antibody, using a neutrophil mediated opsonophagocytic
15 bactericidal assay after 2 hours of incubation at 37°C.

16 V. BRIEF DESCRIPTION OF THE DRAWINGS

17 **Figure 1**

18 Figure 1 shows that when several pools of human standard intravenous
19 immunoglobulin were analyzed, there was a marked difference in the antibody
20 activity to S. epidermidis as measured by an antigen binding assay (ELISA,

-11-

1 highest O.O. reading at 1 1/2 hrs using 1:100 Dil). These were large pools of
2 IgG, purified by several companies using various techniques. Of three pools
3 with the highest titers, two were from Cutter Laboratories, Berkeley
4 California, (40P07, 40R09) and one was from Sandoz, East Hanover, N.J.
5 (069). One preparation from Cutter also had next to the lowest activity
6 (2801). These data show that standard unscreened human immunoglobulin has
7 variable levels of antibody to S. epidermidis and that no single method used to
8 prepare the immunoglobulin or utilizing a large donor pool size will ensure
9 good antibody activity to S. epidermidis. In addition, a donor was shown to
10 have high antibody activity (Sam) to S. epidermidis demonstrating the
11 feasibility of identifying units of plasma or, plasma donors with high levels of
12 antibodies to staphylococcus.

13 Figure 2

14 Figure 2 shows that using an in vitro functional (opsonic) assay that
15 measures the ability of immunoglobulin to promote phagocytosis and killing of
16 S. epidermidis by neutrophils in the presence of complement, that opsonic
17 activity is also variable in various lots and preparations of standard human
18 immunoglobulin. The figure also shows that the immunoglobulins identified
19 by ELISA as having high levels of antibody to S. epidermidis also had high
20 levels of functional antibody in vitro. This is critical since this study shows
21 that IgG that binds to TCA extracted S. epidermidis antigen will promote

-12-

1 phagocytosis and killing of S. epidermidis. Therefore, using in vitro screening
2 assays, one could select a Directed Human Immune Globulin for S.
3 epidermidis that would have reliable levels of antibody to prevent or treat S.
4 epidermidis infections.

5 It also shows that unscreened immune globulin would not
6 provide reliable protection, since many standard human immunoglobulin lots
7 have little or no opsonic activity for S. epidermidis. Hence, standard human
8 immune globulin would not ensure uniformly high levels of antibody to SE and
9 would not be uniformly protective despite the fact that large numbers of donors
10 might be expected to provide good levels of antibody to a common bacteria
11 such as S. epidermidis.

12 Figure 3

13 Figure 3 shows that Directed Immune Globulin protects animals from
14 developing prolonged S. epidermidis bacteremia while standard immune
15 globulin did not. Animals treated with Directed Immune Globulin had lower
16 peak bacteremia levels (9.2×10^2 vs. 6.5×10^3) and cleared the bacteremia
17 more efficiently (at 72 hours, 5 bact. per ml vs. 380 bact. per ml; geometric
18 mean level). In addition 72 hours after infection, 18/24 (75%) animals given
19 Directed Immune Globulin had cleared their bacteremia and 100% survived,
20 while only 4/20 (20%) animals given standard immune globulin died and only
21 1/16 (6%) cleared their bacteremia during that 72 hour period. In addition to

-13-

1 prevention, since Directed Immune Globulin enhanced S. epidermidis
2 clearance, it would be a valuable adjunct to antibiotic therapy for people
3 infected with S. epidermidis, since many of these patients have impaired
4 immunity and may not clear the bacteria efficiently.

5 VI. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

6 EXAMPLES

7 The herein offered examples provide methods for illustrating, without any
8 implied limitation, the practice of this invention in the production of Directed
9 Human Immune Globulin for Staphylococcus epidermidis and the use of said
10 Immune Globulin for the prevention or treatment of infections caused by
11 Staphylococcus epidermidis.

12 The profile of the representative experiments have been chosen
13 to illustrate methods for producing Directed Human Immune Globulin to S.
14 epidermidis and to demonstrate its usefulness to prevent or treat S. epidermidis
15 infections.

16 Materials and Methods

17 Staphylococcal Strains: Although any S. epidermidis strains
18 could be used, in these experiments we used two strains from the American

-14-

1 Type Culture Collection, Rockville, MD (ATCC #31432 and ATCC #35984).
2 A clinical isolate (Hay) from the blood of a child with S. epidermidis sepsis
3 was also used and is also on deposit at the American Type Culture Collection.

4 Materials and Methods

5 Immunoglobulin: Standard Intravenous Immunoglobulin was
6 used in these experiments to represent large immunoglobulin pools.
7 Preparations from several companies were analyzed for comparison, to include
8 Gamimmune, Cutter Laboratories Inc. Berkeley, California; Sandoglobulin,
9 Sandoz, East Hanover, N.J.; Gammagard, Hyland, Los Angeles, California.
10 Serum from individual donors were also analyzed for antibody activity to S.
11 epidermidis.

12 Trichloroacetic Acid (TCA) Antigen Extraction

13 Staphylococcus epidermidis strains (ATCC #35984, ATCC
14 #31432 and Hay) were grown to log phase at 37°C in 1000 ml of Tryptic Soy
15 Broth (Difco). The bacteria were then centrifuged at 2500 RPM for 10
16 minutes and the supernatant was aspirated and discarded. The bacterial button
17 was resuspended in 200 ml of 2% trichloroacetic acid (TCA) and stirred
18 overnight at 4°C. The mixture was then centrifuged at 2500 RPM for 10
19 minutes and the supernatant aspirated. To the supernatant, 4 volumes of
20 absolute ethanol were added and refrigerated overnight at 4°C. After
21 centrifugation at 2500 RPM for 10 minutes, the supernatant was removed and

-15-

1 discarded. Then, five milliliters of normal saline was added to the antigen
2 precipitate, it was cultured to ensure sterility and then lyophilized for storage.

3 Antigen Binding Studies Using Enzyme-Linked
4 Immunoabsorbent Assay (ELISA)

5 S. epidermidis Antigen was dissolved in carbonate buffer at a
6 concentration of 25 micrograms/ml. To each well of A 96-well flat-bottomed
7 microtiter plate (NUNC, Roskilde, Denmark) 100 microliters were added and
8 stored at 4°C until used. Immunoglobulin was diluted to 1% and 2-fold
9 dilutions prepared in phosphate-buffered saline-Tween . To each well was
10 added 100 microliters of the serial dilutions and the plates were incubated for 1
11 hour at 4°C. The plates were washed four times with H₂O-Tween , Alkaline
12 phosphatase linked goat anti-Human IgG (100 microliters;1:250) was added,
13 the plates were incubated for 1 hour at 4°C and then washed H₂O-Tween and
14 100 microliters of P-nitrophenyl phosphate substrate in diethanolamine buffer
15 were added. After 90 minutes of incubation at room temperature, the color
16 development was determined by absorbance at 405 nm.

17 Opsonic Assay:

18 To determine the functional antibody to S. epidermidis in the
19 immune globulin pools and sera, a neutrophil mediated bactericidal assay was

-16-

1 used. Neutrophils were isolated from adult venous blood by dextran
2 sedimentation and ficoll-hypaque density centrifugation. Utilizing a microtiter
3 plate assay that requires a total volume of 0.1 ml/well, washed neutrophils
4 (approximately 10^6 cells) were added to round-bottomed microtiter wells along
5 with 3×10^4 approximately mid-log phase bacteria. Newborn rabbit serum (10
6 microliters; screened to assure absence of antibody to S. epidermidis) was
7 used as a source of active complement. Forty microliters of 5% standard
8 immune globulin (or serum) was added and the microtiter plates were
9 incubated at 37°C with constant, vigorous shaking. Samples (10 microliters)
10 were taken from each well at zero time and after 2 hours of incubation,
11 diluted, vigorously vortexed to disperse the bacteria and cultured on blood agar
12 plates overnight at 37°C to quantitate the number of viable bacteria. Controls
13 consisted of neutrophils alone, complement alone and neutrophils plus
14 complement.

$5.6 \times 10^8 / \text{ml}$
 $5.0 \times 10^8 / \text{ml}$
 $1.0 \times 10^8 / \text{ml} = 10 \text{ mg}$

15 Staphylococcal Sepsis Model:

16 A suckling rat model was used to determine the in vivo activity
17 of antibody to S. epidermidis. Wistar rats (2 days old) were given 0.2 ml of
18 20% Intralipid (Cutter, Berkeley California,) intraperitoneally at 0800 and
19 1400. At three days of age each animal was again given, 0.2 ml of 20%
20 intralipid at 0800 and 1400 and 0.2 ml of 5% immunoglobulin or serum was
21 given IP. Shortly after the last dose of intralipid, 0.05 ml (approx. 5×10^7)

-17-

1 mid log phase S. epidermidis were injected subcutaneously just cephalad to the
2 tail. Suckling rats less than 24 hours old also develop lethal S. epidermidis
3 sepsis when infected with 10^7 - 10^8 S. epidermidis subcutaneously. To analyze
4 bacteremia levels in selected animals, 0.01 ml of blood was obtained from the
5 tails of the suckling rats, 24, 48, and 72 hours after infection. The blood was
6 collected under sterile conditions in micropipettes and serially diluted in
7 Tryptic Soy Broth (Difco). Bacteria were subcultured onto plates to ensure S.
8 epidermidis bacteremia and all animals were followed five days to determine
9 survival.

10 Results

11 Antigen Binding Activity of Human Immunoglobulin for S. 12 epidermidis.

13 The results of the ELISA testing of several standard
14 immunoglobulin preparations for antibody to S. epidermidis are presented in
15 Figure 1. Most standard immune globulins contained low levels of antibody to
16 S. epidermidis. However, by screening for antibody to TCA extracted antigens
17 of S. epidermidis, some immunoglobulin lots and serum from one volunteer
18 donor were found to have increased levels of antibody to S. epidermidis (O.D.
19 readings 1.014, 1.026, and 1.002). Variations in antibody to S. epidermidis
20 occurred between preparations prepared by different techniques and lot to lot
21 variation in a single preparation was seen as well, indicating that all
22 immunoglobulin pools were not the same.

-18-

1 Opsonic Activity of Human Immunoglobulins for *S. epidermidis*.

2 All antibody directed against a given organism may not enhance
3 immunity and provide enhanced protection from infection. Stated differently,
4 antibodies can bind to bacteria and yet not enhance opsonization in vitro or
5 clearance from the blood of an infected host. Therefore a functional assay was
6 also utilized to determine if the antibody to *S. epidermidis* detected by ELISA
7 was also capable of promoting phagocytosis and killing of the organism by
8 neutrophils (Figure 2). Opsonic antibody activity ranged from low (<25%
9 bactericidal activity), to moderate activity (25-80%) and a few had high
10 bactericidal activity (>80%). Therefore two standard human immune globulin
11 preparations with high bactericidal activity were selected as Directed Human
12 Immune Globulin for *S. epidermidis* based on in vitro assays that measured
13 antibody binding to TCA *S. epidermidis* antigens and opsonic antibody activity
14 determined by in vitro testing. Serum from a single donor also had good
15 opsonic activity for *S. epidermidis* (>80% opsonophagocytic bactericidal
16 activity). While serum and plasma from several individuals have been studied
17 only this donor had high opsonic activity. Therefore donor screening could
18 detect individual blood or plasma donors that could contribute immunoglobulin
19 that could be pooled as an alternate method to produce a

-19-

1 Directed Human Immune Globulin for S. epidermidis. In addition blood or
2 plasma units could be screened for pooling as well.

3 Animal Protection Studies

4 Description of Tables

5 Table 1

6 Table 1 shows the effect of Directed Human Immunoglobulin for
7 S. epidermidis (40R09) (which was selected by ELISA and opsonic assay
8 screening) compared to standard human immunoglobulin (that had moderate
9 activity for S. epidermidis) and saline control. Table 1 shows that untreated
10 control animals had about a 50% mortality while animals given Directed
11 Immune Globulin for S. epidermidis were fully protected (NO mortality).
12 Standard immune globulin gave only partial protection. Other standard
13 immune globulin lots with lower levels of antibody to S. epidermidis would be
14 even less effective, since mortality was much higher with saline. However,
15 one would not expect that Directed Immune Globulin would be always 100%
16 effective, but that it would consistently improve survival over standard immune
17 globulin or untreated animals.

18 Table 2

19 Table 2 demonstrates that Directed Immune Globulin produced
20 in rabbits by immunization (S. epidermidis vaccine) produced survival similar

-20-

1 to Directed Human Immune Globulin produced by screening immunoglobulin
2 for antibody to S. epidermidis. Immunization of individuals with S.
3 epidermidis vaccine and collecting plasma for immunoglobulin extraction
4 would be another method for producing Directed Human Immune Globulin for
5 preventing or treating S. epidermidis infections.

6 Table 3

7 Table 3 shows that intralipid causes a dose related increased
8 mortality in suckling rats infected with S. epidermidis. Control animals
9 receiving Intralipid alone had 100% survival (43/43) while immature rats given
10 16 gm/kg of Intralipid had only 46% survival (6/13). The high dose of
11 Intralipid appears to impair the immune system sufficiently to allow the
12 normally avirulent S. epidermidis to overwhelm the baby animals.

13 Table 4

14 Table 4 shows that normal 3 day old suckling rats not given
15 Intralipid, but infected with S. epidermidis develop bacteremia. However,
16 over 72 hrs their immune system is able to clear the organisms from the blood
17 and all of the baby rats survive.

-21-

1 Table 1 shows the Directed Human Immune Globulin for S.
2 epidermidis (selected by screening standard immunoglobulin for opsonic or
3 antigen binding activity for S. epidermidis) provides complete protection from
4 lethal infection in the setting of impaired immunity with Intralipid while
5 standard immune globulin (with moderate antibody levels) had only partial
6 protection (1 out of 5 animals died compared to about 50% with saline).
7 Additional studies with another immunoglobulin preparation, (Alpha
8 Pharmaceuticals; Directed Human Immune Globulin 8016A >90% opsonic
9 activity, versus standard human immune globulin, 8007A < 50% opsonic
10 activity) showed that the Directed Human Immune globulin also provided
11 enhanced survival (8016A-64/95 (67%) vs. 8007A-39/90 (43%)) over standard
12 human immune globulin. Even more striking was the fact that the Directed
13 Human Immune Globulin decreased the peak level of S. epidermidis
14 bacteremia and promoted rapid clearance of the bacteria (Figure 3). These
15 studies showed that antibody was important for protection against S.
16 epidermidis enhanced bacterial clearance from the blood and could be an
17 effective prophylactic or therapeutic modality even in the immature host with
18 impaired immunity. Many of the animals treated with standard human immune
19 globulin remained bacteremic 72 hours after infection while only 1/20 animals
20 was still bacteremic at 72 hours after receiving the Directed Human Immune
21 Globulin. In addition the mean bacteremia level at 72 hours was

-22-

1 markedly different (bacteremia with Directed Human Immune Globulin $0.5 \times$
2 10^1 vs. bacteremia with standard human immune globulin 3.8×10^2).

3 In further studies, rabbit Directed Immune Globulin for S.
4 epidermidis was produced by immunizing rabbits with S. epidermidis vaccine.
5 The vaccine induced Directed Immune Globulin was compared with Directed
6 Human Immune Globulin produced by screening immunoglobulin for antibody
7 to S. epidermidis (Table 2). Vaccine induced Directed Immune Globulin had
8 similar protective activity to Directed Human Immune Globulin produced by
9 screening (9/11 vs. 12/13 survived) and each was better than controls (11/19
10 survived). These data show that S. epidermidis vaccine induced antibody
11 could be used for prevention and treatment of S. epidermidis infections and
12 that vaccine could be used to produce a Directed Human Immune Globulin.

13 TABLE 3

14 Many bacteria such as S. epidermidis are not pathogenic in
15 normal people. However, in babies with an immature immune system or
16 impaired immunity as is seen with intralipid, S. epidermidis may cause sepsis
17 and death. It is critical therefore, that any animal model to test antibody
18 effectiveness should include these factors. To our knowledge this is the first
19 time that antibody to Staphylococcus epidermis has been shown to provide
20 protection and enhance bacterial clearance in an immature and/or

-23-

1 immunosuppressed host. Intralipid given in dosage up to 16 gm/kg did not
2 cause death in any baby animals (controls, table 3). In the absence of
3 Intralipid, the 3 day old animals will become bacteremic with S. epidermidis
4 after infection, but will clear the infection over 72 hours and survive (Table 4).
5 However, Intralipid did impair immunity in a dose related fashion and when
6 the 3 day old animals were infected with S. epidermidis lethal sepsis occurred
7 in up to 67% of the animals. Baby rats in the first day of life also do not clear
8 bacteremia well (due to immature immunity) and develop lethal sepsis. In
9 these models baby rats were unable to clear the S. epidermidis bacteremia and
10 developed lethal sepsis. Directed Human Immune Globulin was able to
11 enhance survival and promote bacterial clearance while standard human
12 immune globulin did not enhance clearance (Fig 3).

13 TABLE 4

14 When SE is injected into normal baby rats, they become
15 bacteremic in 2 hours and then begin to slowly clear the bacteria from the
16 blood. All of the animals cleared the bacteremia 72 hours after the infection.
17 thus suggesting that under normal circumstances neonatal immunity while
18 impaired can eventually control SE. However, studies in rats infectedd with S.
19 epidermidis shortly after birth have demonstrated that they can also develop a
20 lethal infection.

TABLE I
Effectiveness of Standard Immune Globulin
and Directed Immune Globulin to
***Staphylococcus epidermidis* in Providing Protection**
from lethal *S. epidermidis* Infection
in a Suckling Rat Model

Immunoglobulin Type	Treated	Died	% Mortality
Directed Immune Globulin * (40R09)	24	0	0
Standard Immune Globulin *	20	4	20%
Control			
Untreated**	13	7	54%
Uninfected**	11	0	0

* #20-23 - 3/25/90

** #8 - 2/11/90, #4 - 1/29/90

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

TABLE 2

Comparison of Therapeutic Efficacy of
Vaccine Induced Anti-staphylococcal
Directed Immune Globulin with Screened
Directed Immune Globulin in a *S. epidermidis* Sepsis Model*

Treatment	Exp.	Treated	Survived	% Survived
Vaccine Induced Directed Immune Globulin	16,19	11	9	82%
Screened Directed Immune Globulin (40R09)	17,18	13	12	92%
Saline Control	16,17 18,19	19	11	58%

* 1990 Studies

TABLE 3

Animal Model: Effect of Intralipid Dosage on
Staphylococcus epidermidis mortality in suckling rats

<u>Intralipid</u> <u>Dose</u>	<u>Infected</u>	<u>Survival</u> <u>Control</u>
4 gm/kg	10/10 (100%)	7/7 (100%)
8 gm/kg	10/13 (76%)	9/9 (100%)
12 gm/kg	7/12 (58%)	11/11 (100%)
16 gm/kg	6/13 (46%)	11/11 (100%)
*16 gm/kg	2/6 (33%)	5/5 (100%)

11 Infection with S. epidermidis (Haywood); approximately 10⁷ bacteria SQ.

12 Standard model starts IL on day 2 of life with infection after last IL dose on day 3 if full 4 doses given.

13 *IL started on day 1 of life with infection after the 4th dose on day 2.

-27-

TABLE 4

Staphylococcus epidermidis Bacteremia Levels in Normal Suckling
Rats Given Normal Saline Instead of Intralipid

Time Post Infection	Number Bacteremic	Per Cent Bacteremic	Bacteremia Level *
2 hours	8/8	100	3.8×10^2
4 hours	7/8	87.5	1.3×10^2
6 hours	8/8	100	7.5×10^2
24 hours	6/8	75	8.8×10^1
48 hours	3/8	37.5	0.5×10^1
72 hours	0/8	0	0
Exp. 93+94: 8/8 survived			

*Mean number of bacterial per ml of blood

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

-28-

1 We claim:

2 1. A Directed Human Immune Globulin for the prevention or
3 treatment of Staphylococcus epidermidis infections.

4 2. A Directed Human Immune Globulin of Claim 1 which
5 contains a measured level of anti-staphylococcal IgG antibodies that react with
6 surface antigens of Staphylococcus epidermidis and promote phagocytosis and
7 killing of Staphylococcus epidermidis in vitro and/or protection against
8 Staphylococcus epidermidis in vivo.

9 3. The Directed Human Immune Globulin of Claim 2 wherein
10 the measured level of anti-staphylococcal IgG antibodies has an opsonic
11 activity within the range of about 80 to about 100 percent.

12 4. A pharmaceutical composition comprising an amount of
13 Directed Human Immune Globulin of Claim 1 sufficient to prevent or treat
14 infections by S. epidermidis and a pharmaceutically acceptable carrier therefor.

15 5. A pharmaceutical composition comprising a Directed Human
16 Immune Globulin of Claim 2.

-29-

1 6. A pharmaceutical composition comprising a Directed Human
2 Immune Globulin of Claim 3.

3 7. A method of preparing a Directed Human Immune Globulin
4 of Claim 1 by screening serum, plasma, or an immunoglobulin pool by S.
5 epidermidis ELISA or Opsonic Assays.

6 8. The method of Claim 7 wherein serum is screened by S.
7 epidermidis ELISA or Opsonic Assays.

8 9. The method of Claim 8 wherein the serum is screened by S.
9 epidermidis ELISA.

10 10. The method of Claim 8 wherein the serum is screened by
11 S. epidermidis Opsonic Assays.

12 11. The method of Claim 7 wherein the plasma is screened by
13 S. epidermidis ELISA or Opsonic Assays.

14 12. The method of Claim 11 wherein the plasma is screened by
15 S. epidermidis ELISA.

-30-

1 13. The method of Claim 11 wherein the plasma is screened by
2 S. epidermidis Opsonic Assays.

3 14. The method of Claim 7 wherein the immunoglobulin pool is
4 screened by S. epidermidis ELISA or Opsonic Assays.

5 15. The method of Claim 14 wherein the immunoglobulin pool
6 is screened by S. epidermidis ELISA.

7 16. The method of Claim 14 wherein the immunoglobulin pool
8 is screened by S. epidermidis Opsonic Assays.

9 17. A method of preparing a Directed Human Immune Globulin
10 of Claim 1 comprising the steps of: (a) immunizing plasma donors and (b)
11 removing plasma from said donors for Directed Immune Globulin preparation.

12 18. A method of assessing the protective level of Direct
13 Human Immune Globulin by using an immature or intralipid induced lethal
14 model to provide minimum protective standard comprising the steps of: (a)
15 screening with in vitro assays and (b) using animal lethality tests to ensure that
16 the immunoglobulin preparation provided protective antibody to S.
17 epidermidis.

-31-

1 19. A method of treating a host with a therapeutically- effective
2 amount of S. epidermidis of Directed Human Immune Globulin of Claim 1 by
3 intravenous administration thereof.


4 20. A method of treating a host with a therapeutically effective
5 amount of S. epidermidis of Directed Human Immune Globulin of Claim 1 by
6 intramuscular administration thereof.

7 21. The method of Claim 19 wherein the host is treated prior to
8 infection with S. epidermidis.

9 22. The method of Claim 20 wherein the host is treated after
10 infection with S. epidermidis.

Figure 1

Antigen Binding Activity of Human Immunoglobulin for Staphylococcus epidermidis



ELISA - 10/13/89
Haywood TCA extract
Using 1 1/2 hr. highest
O.D. at 1:100

Immunoglobulin Pool

*Immunoglobulin from Human donor

Figure 2

Opsonic Activity of Human Immunoglobulin
for Staphylococcus epidermidis *





Figure 3

Effect of Standard Immune Globulin and Directed Immune Globulin on Clearance of *S. epidermidis* from the Blood of Animals with *S. epidermidis* Se



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/09830

A. CLASSIFICATION OF SUBJECT MATTER																										
IPC(5) : Please See Extra Sheet.																										
US CL : 530/389.5; 424/9, 87, 92; 435/7.92																										
According to International Patent Classification (IPC) or to both national classification and IPC																										
B. FIELDS SEARCHED																										
Minimum documentation searched (classification system followed by classification symbols)																										
U.S. : 530/389.5; 424/9, 87, 92; 435/7.92																										
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																										
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)																										
CAS ONLINE, MEDLINE, APS																										
C. DOCUMENTS CONSIDERED TO BE RELEVANT																										
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																								
Y	US, A, 4,027,010 (Kiselev et al.) 31 May 1977, the Abstract.	1-6, 17																								
Y	US, A, 4,197,290 (Yoshida et al.) 08 April 1980, the Abstract.	1-6, 17																								
X Y	Journal of Applied Bacteriology, Volume 63, issued 1987, Y. Ichiman et al., "Protective antibodies in human sera against encapsulated strains of Staphylococcus epidermidis", pages 165-169, especially page 165.	1-6 1-16, 18-22																								
Y	Infection and Immunity, Volume 42, No. 3, issued December 1983, T. E. West et al., "Detection of anti-teichoic acid immunoglobulin G antibodies in experimental Staphylococcus epidermidis endocarditis", pages 1020-1026, especially page 1020.	1-16, 18-22																								
Y	Journal of Clinical Microbiology, Volume 23, No. 2, issued February 1986, F. Espersen et al., "Enzyme-linked immunosorbent assay for detection of Staphylococcus epidermidis antibody in experimental S. epidermidis endocarditis", pages 339-342, especially page 339.	1-16, 18-22																								
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																										
<table border="0"> <tr> <td colspan="2">* Special categories of cited documents:</td> <td>* T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>* A</td> <td>document defining the general state of the art which is not considered to be part of particular relevance</td> <td>* X</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>* E</td> <td>earlier document published on or after the international filing date</td> <td>* Y</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>* L</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>* G</td> <td>document member of the same patent family</td> </tr> <tr> <td>* O</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>* P</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:		* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	* A	document defining the general state of the art which is not considered to be part of particular relevance	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	* E	earlier document published on or after the international filing date	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	* L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* G	document member of the same patent family	* O	document referring to an oral disclosure, use, exhibition or other means			* P	document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:		* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																							
* A	document defining the general state of the art which is not considered to be part of particular relevance	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																							
* E	earlier document published on or after the international filing date	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																							
* L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* G	document member of the same patent family																							
* O	document referring to an oral disclosure, use, exhibition or other means																									
* P	document published prior to the international filing date but later than the priority date claimed																									
Date of the actual completion of the international search		Date of mailing of the international search report																								
27 JANUARY 1993		24 FEB 1993																								
Name and mailing address of the ISA/ Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231		Authorized officer CHRISTINA CHAN																								
Facsimile No. NOT APPLICABLE		Telephone No. (703) 308-0196																								

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/09830

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J Clin Pathol, Volume 39, issued 1986, L. Clark et al., "Opsonic activity of intravenous immunoglobulin preparations against Staphylococcus epidermidis", pages 856-860, especially page 856.	1-16, 18-22
Y	The Lancet, issued 18 October 1980, G. W. Fischer et al., "Diminished bacterial defences with intralipid", pages 819-820, especially page 819.	18
A	The New England Journal of Medicine, Volume 323 No. 5, issued 02 August 1990, J. O. Klein, "From Harmless commensal to invasive pathogen coagulase-negative Staphylococci", pages 339-340.	1-22

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/09830

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (5):

C07K 15/06; A61K 35/16, 39/40, 39/085, 39/395, 49/00; C12Q 1/00; G01N 33/536

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

I. Claims 1-6 and 19-22, drawn to an immune globulin, a composition, a method of preparing an immune globulin and a method of using the immune globulin, Classes 530, 435 and 424, Subclasses 389.5, 7.92 and 87, respectively.

II. Claim 17, drawn to a method of preparing an immune globulin, Class 424, Subclass 92.

III. Claim 18, drawn to a method of assessing the protective level of an immune globulin, Class 424, Subclass 9.

The inventions are distinct, each from the other because of the following reasons:

Inventions II and I are related as process of making and product made. In the instant case the product as claimed can be made by materially different processes such as the two different processes in Groups I and II.

Further, the inventions as grouped are distinct, each from the other, because they represent different inventive endeavors. The inventions of Groups I-II would not suggest the invention of Group III.